Disclosure statement: The authors have nothing to disclose 40 2 Alterations during development of metabolic key organs such as the endocrine pancreas affect the 41 phenotype later in life. There is evidence that in utero or perinatal exposure to bisphenol-A (BPA), 42 leads to impaired glucose metabolism during adulthood. However, how BPA exposure during 43 pregnancy affects pancreatic β-cell growth and function in offspring during early life has not been 44 explored. We exposed pregnant mice to either vehicle (Control) or BPA (10 and 100 µg/kg/day, 45 BPA10 and BPA100) and examined offspring on postnatal days (P) P0, P21, P30 and P120. BPA10 46 and BPA100 mice presented lower birth weight than Control and subsequently gained weight until 47 day 30. At that age, concentration of plasma insulin, C-peptide and leptin were increased in BPA-48 exposed animals in non-fasting state. Insulin secretion and content were diminished in BPA10 and 49 maintained in BPA100 compared to Control. A global gene expression analysis indicated that genes 50 related with cell division were increased in islets from BPA-treated animals. This was associated with 51 an increase in pancreatic β-cell mass at P0, P21 and P30, together with increased β-cell proliferation 52 and decreased apoptosis. On the contrary, at P120, BPA treated animals presented either equal or 53 decreased β-cell mass compared to Control and altered fasting glucose levels. These data suggest that 54 in utero exposure to environmentally relevant doses of BPA alters the expression of genes involved in 55 β-cell growth regulation, incrementing β-cell mass/area and β-cell proliferation during early life. An 56 excess of insulin signaling during early life may contribute to impaired glucose tolerance during 57 adulthood. 58 3
INTRODUCTION 59
Chronic diseases like diabetes and obesity are due to gene-by-environment interactions over time, 60 starting during fetal development. The developmental origins of health and disease (DOHaD) 61 hypothesis proposes that "an adverse environment experienced by a developing individual can 62 increase the risk of diseases later in life" (1) . This hypothesis was formulated after the work by Barker 63
(2) based on the strong association between poor nutrition during intrauterine life and the increased 64 incidence of metabolic disorders among the offspring. Thus, maternal nutrition during early 65 development is considered a major intrauterine environmental factor influencing the development and 66 progression of obesity and type 2 diabetes later in life. In addition, the metabolic conditions of the 67 mother affect the development of the endocrine pancreas. This is extremely important since fetal life 68 represents a critical period of time in which a correct β-cell function and an appropriate β-cell mass 69 are set in place. A substantial number of animal models have been developed to elucidate the 70 consequences and mechanisms in maternal overnutrition and malnutrition. The former includes 71 animal models of obesity or high fat diet (3-5) and the later include low protein diet (6, 7) or low 72 energy diet (8-10) as well as models of hypoxia (11), gestational diabetes (12), hyperglycaemia (13) 73 and insulin resistance (14) . In most of these models β-cell mass, β-cell function or both are altered. 74
Exposure to EDCs during pregnancy has been recognized for decades to cause adverse outcomes in 75 progenies, both in humans and in animal models (15, 16) . One early and well-studied example was in 76 utero exposure to diethylstilbestrol (DES), a potent non-steroidal estrogen drug designed by Dodds in 77 1936 (17, 18) and prescribed from 1940 to 1975 as an antiabortive drug. In the 1970s it was proved 78 that exposed daughters presented clear-cell adenocarcinomas at an early age (19, 20) . Remarkably, 79
work with animal models reproduced the effects clinically detected in humans (21). Like DES, BPA 80 was demonstrated to have estrogenic activity at about the same time (17, 18) , but because DES 81 resulted to have stronger activity than BPA, DES was used in clinical practice. 82
In the 1950s BPA was rediscovered as a compound that could be polymerized to make polycarbonate 83 plastic. From that moment it has been extensively used in the plastic industry with approximately 15 84 billion pounds per year of BPA produced annually in the world (22) 85
In addition to its role as the base component of polycarbonate plastic, BPA is used to produce epoxy 86 resins for the coating of pipes and metal equipment and the lining of food cans (23) as well as a 87 plasticizer in the manufacture of other plastics such as PVC (24). Heat, acid or basic media have been 88
shown to cause the leaching of the monomer to the environment (25) . 89
90
It was described that BPA has lower affinity than 17-β-estradiol for the nuclear receptors ERα and 91
ERβ which will act as transcription factors binding to estrogen response elements in the DNA (26, 92 27 ). More recently we have proposed that it can behave also as a potent estrogen (within the 93 picoMolar-nanoMolar range) in β-cells when binding ERα and ERβ out of the nucleus. In this 94 manner, BPA triggers the activation of different signaling pathways, involving kinases as well as the 95 activation of other transcription factors which could explain many of the low doses effects of BPA 96
BPA is a widespread EDC which has been found in the urine of 93% of USA citizens (31). Its 98 concentration ranges within the nanograms per mL reported by some authors (32-34) and the 99 picogram per mL range reported by other authors (35). In any case, exposure of mice and rats to BPA 100 at low doses during pregnancy, or pregnancy and lactation, produced alterations in blood glucose 101 homeostasis and β-cell function in male adult offspring (36-40). The adult phenotype is dependent on 102 gender, age, dose and timing of exposure; yet in the majority of reports there is insulin resistance, 103 glucose intolerance, hyperinsulinemia and alteration in blood adipokine levels. In particular 104 alterations in glucose homeostasis was observed in adult offspring (between 3 and 8 months of life) 105 after BPA exposure through gestation or gestation and lactation in OF-1 mice, CD-1 mice or rats at 106 doses of 3.5, 5, 10, 40, 50 or 100 µg/kg/day (36) (37) (38) (39) (40) (42) (43) (44) (45) (46) . No effect on glucose metabolism was 107 observed when exposure occurred at lower levels 2.5 ng/kg/day (47). 108
109
In the present study, we used pregnant mice exposed to environmentally relevant doses of BPA to 110 determine how BPA exposure affects glucose homeostasis, β-cell function and β-cell mass at an early 111 age in offspring. Based on the United States-Environmental Protection Agency (U.S.-EPA) criterion 112
Islet cell isolation 150
Pancreatic islets of Langerhans were isolated by collagenase (Sigma, Madrid, Spain) digestion 151 (modified from (48)) The solution used for the isolation of the islets of Langerhans contained (in 152 mmol/l): 115 NaCl, 10 NaHCO 3 , 5 KCl, 1.1 MgCl 2 , 1.2 NaH 2 PO 4 , 2.5 CaCl 2 , 25 HEPES, and 5 D-153 glucose, pH 7.4, as well as 0.25% BSA. Freshly isolated islets were used for insulin secretion and 154 content measurements after 2 hours of recovery. 155
156

Glucose and insulin tolerance tests 157
For intraperitoneal glucose tolerance tests (ipGTT), animals were fasted for 12 h, and blood samples 158 were obtained from the tail vein. Animals were then injected intraperitoneally with 2g/kg body weight 159 of glucose, and blood samples were taken at the indicated intervals. 160
For intraperitoneal insulin tolerance tests (ipITT), fed animals were used. Animals were injected 161 intraperitoneally with 0.75 IU/kg body weight of soluble insulin (Lilly), and blood samples were 162 obtained from the tail vein. Blood glucose was measured in each sample using an Accu-check 163 compact glucometer (Roche, Madrid, Spain). Levels of glycemia after insulin injection are expressed 164 as % of glycemia compared to basal glycemia levels in fed state. 165
166
Serum analysis 167
Blood samples were collected for biochemical analysis at decapitation in fed or fasted (12 hours) state 168 animals. Serum samples were obtained by centrifugation for 15 minutes at 1200 rpm at 4ºC. Samples 169 were stored at -80ºC. The serum insulin level was analyzed by Ultra Sensitive Mouse Insulin ELISA 170 Kit (Crystal Chem, Downers Grove, IL). C-peptide level was determined using C-peptide (mouse) 171 ELISA (Alpco immunoassays, Salem, NH). Leptin level was analyzed by Mouse Leptin ELISA kit 172 (Crystal Chem, Downers Grove, IL). Non-esterified fatty acids (NEFAs) were measured using a 173
NEFA-HR(2) kit for serum determination (Wako). 174
Triglycerides and Cholesterol levels were measured using sample provide from the tail vein and were 175 analyzed using Accutrend Plus (Roche, Madrid, Spain) . 176
Insulin secretion and content. 178
Freshly isolated islets were left to recover in the isolation medium for 2h in the incubator at 37ºC and 179 0.5% CO 2 . After recovery, groups of 5 islets were transferred to 400µl of a buffer solution containing 180 140 mM NaCl, 4.5 mM KCl, 2.5 mM CaCl 2 , 1 mM MgCl 2 , 20mM HEPES and the corresponding 181 glucose concentration (3, 8 or 16mM) with final pH at 7.4. Afterwards, 100μl of the buffer solution 182
with the corresponding glucose concentration with 5% BSA was added. Then, the medium was 183 collected and insulin was measured in duplicate samples by radioimmunoassay using a Coat-a-Count 184 kit (Siemens, Los Angeles, CA, USA). systematically by capturing images from non-overlapping fields with a digital camera (Kappa ACC1). 231
The islet cross-sectional area and total pancreatic area were measured using the analysis program 232
Metamorph Software. Beta cell mass (mg per pancreas) was calculated by multiplying relative 233 insulin-positive area (the ratio of insulin positive area over total pancreas area) by pancreas weight. 234
For quantification of the number of islets per area, only islets with more than 5 positive-stained cells 235 were scored. 236 237 β-cell replication and apoptosis 238
The same mice used for pancreatic β-cell area (5-8 different mice per experimental condition from 5-8 239 different litters (see figure legend)), were given intraperitoneal injections of BrdU (100 µg/g) 6 hr 240 before sacrifice. Pancreatic tissue was collected, fixed, and processed as described above. After 241 dehydration, sections were heated to 100°C in the presence of citrate buffer (10 mM) for 20 min and 242 immersed in 2 N HCl for 5 min, followed by incubation in a 0.1 M borax solution for 10 min at RT 243 and washed with phosphate-buffered saline. Slides were then blocked by incubating for 1h in 3% 244 bovine serum albumin in phosphate-buffered saline. Samples were then incubated with antibodies for 245 insulin (1:100, rabbit polyclonal; Santa Cruz Biotechnology, Madrid, Spain) (table 1) and BrdU 246
(1:100, mono-clonal; DAKO, Barcelona, Spain) (table 1) overnight at 4°C. After incubation with 247 secondary anti-bodies (Alexa Fluor, Molecular Probes, Barcelona, Spain), sections were incubated 248 with Hoechst 33342 (Alexa Fluor, Molecular Probes, Barcelona, Spain) and then mounted using 249
ProLong Gold Antifade Reagent (Invitrogen, Barcelona, Spain). Images were acquired for triple-250 stained sections. BrdU-positive nuclei were scored only in cells that were also positive for insulin. At 251 least 1200 cells per pancreas were counted. To identify apoptosis, TUNEL was performed by using an 252 in situ cell death detection kit (Roche, Madrid, Spain) according to the manufacturer's specifications 253 for paraffin-embedded tissues. Sections were then washed and stained for insulin as previously 254
described. 255 256
Statistical analysis 257
SigmaStat 3.1 software (Systat Software, Inc., Chicago, IL, USA) was used for all statistical analyses. 258
To assess differences between treatment groups for each exposure paradigm, we used the one-way 259 analysis of variance (ANOVA). We used a post hoc test only when ANOVA gave a statistically 260 significant difference. When data did not pass the parametric test, we used Kruskal-Wallis ANOVA 261 on ranks followed by Dunn's test. We used student t-test when comparing two groups. Results were 262 considered significant at p < 0.05. Data are shown as mean ± SEM. We specified statistic tests used 263 in each experiment in figure legends. 
272
To examine the effects of BPA on the glucose metabolism of offspring, we treated pregnant mice with 273 either vehicle or BPA at doses of 10 or 100 µg/kg/day on GD9-GD16. In total, we had 3 different 274 groups that have been represented in the figures in the following manner: vehicle treated animals 275 (Control, white bars), animals exposed to 10 µg/kg/day of BPA (BPA10, grey bars) and animals 276 exposed to 100 µg/kg/day of BPA (BPA100, black bars). 277 278
Low birth weight and weight changes during P0 and P30 279
Body weights (BWs) from the different groups were measured periodically starting on postnatal day 0 280 (P0). Pups born from BPA10 and BPA100 mothers presented a reduced weight compared to Control 281 (control: 1.76±0.02g; BPA10: 1.47±0.03g; BPA100: 1.59±0.04g) ( Figure 1A ). The BPA10 offspring 282 rapidly gained weight to the same levels as Control, while BPA100 maintained a reduced weight until 283 weaning (P21) ( Figure 1A ). Remarkably, those in the BPA100 group started to gain weight during the 284 period between P21 and P30, reaching a higher body weight than control and BPA10 at P30 (control: 285 22.9±0.5g; BPA10: 23.3±0.6g; BPA100: 25.5±0.9g) ( Figure 1B) . 286 287
Insulinemia, glucose tolerance and insulin sensitivity 288
To evaluate the effect of BPA exposure on glucose homeostasis at P30, intraperitoneal glucose 289 tolerance and insulin tolerance tests were performed. In both BPA10 and BPA100 glucose tolerance 290 and insulin sensitivity were similar to Control ( Figure 1C,D) . Plasma insulin and glucose levels in the 291 fasted state were not significantly changed (Table 2) . Contrarily, plasma insulin in non-fasting state 292 was significantly elevated in BPA10 and BPA100 compared to control (Table2). To determine 293 whether the increase in plasma insulin was a consequence of enhanced insulin release we measured 294 plasma C-peptide levels which is a manner of evaluating pancreatic β-cell insulin secretion (54). C-295 peptide levels were significantly higher in both cases BPA10 and BPA100 indicating that insulin 296 release is increased in BPA exposed animal compared to Control (table2). 297
Leptin plasma levels, which are a marker of adiposity, were elevated more than two fold in BPA 298 animals vs control (table2); particularly in BPA100 mice which presented the highest weight (Figure  299 1B). Levels of cholesterol, triglycerides and NEFA were not significantly changed (Table2). 300 301
Insulin release and insulin content in isolated islets 302
To determine whether the hyperinsulinemia in the non-fasting state was because an enhanced glucose 303 stimulated insulin secretion (GSIS), we isolated whole islet of Langerhans from Control, BPA10 and 304 BPA100 treated mice and we exposed them to increasing glucose concentrations. Figure 1E shows 305 that GSIS was decreased in BPA10 and unchanged in BPA100 compared to Control. Pancreatic 306 insulin content followed the same pattern, it decreased in BPA10 and was similar in BPA100 307 compared to Control ( Figure 1F ). These experiments suggest that hyperinsulinemia in non-fasting 308 state must be related to factors other than enhanced GSIS. were related to different functional categories. Among the ~325 genes that were upregulated, gene 319 ontology analysis revealed that the most enriched categories were those related with cell cycle, 320 mitosis and, in general, with cell division. These changes were more prominent in islets from the 321 BPA10 group and, although to a lower extent, were also observed in the BPA100 group (Figure 2) . 322
Interestingly, the two most upregulated genes in BPA10 islets, Prss3 (also known as Mesotrypsin) 323
and Agr2, although not directly involved in the cell cycle machinery, have been described to act as 324 potent inducers of cell proliferation and tumor progression in several types of cells and cancers 325 (PRSS3 promotes tumor growth and metastasis of human pancreatic cancer) (55). The 326 adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular 327 transformation (56). 328
329
Differential expression of genes identified from the microarray data (Figure 2 ) was validated by qPCR 330 using RNA samples from Control, BPA10 and BPA100 islets at P30. This analysis confirmed that 331 BPA treatment increased the expression of Ccnb1, Cdk1, Mt1, Procr and Idi1, (Figure 3A-E) . 332
Although no significant differences for Mt2, Spa17 and Birc5 were found when performing an 333 ANOVA test, these genes were significantly deregulated in BPA10 samples compared to Control by 334 Student's t-test ( Figure 3F-H) . Expression of Pdx-1 was significantly increased in BPA10 by qPCR 335 analysis, although significant changes were not observed in the microarray ( Figure 3I) . 336
337
BPA treatment increases β-cell mass at P0, P21 and P30 and decreases β-cell mass in P120 offspring 338
Because the expression of many genes involved in cell cycle was increased in P30 islets after BPA 339 exposure, we decided to examine pancreatic β-cell mass at P30. We found an increase in the 340 percentage of β-cell area relative to the total pancreas area which was significant in the case of BPA10 341 ( Figure 4A ), according to the microarray data. Pancreatic β-cell mass was also increased in BPA10 342 and BPA100 ( Figure 4B ). To know whether the increase in β-cell mass was an effect caused during 343 fetal development, lactation or the post-weaning week, we decided to measure β-cell mass at P0 and 344 P21. Notably, both BPA10 and BPA100 offspring at P0 presented a higher relative β-cell mass 345 compared to Control ( Figure 4C ). Increased β-cell mass was also observed at the day of weaning 346 (P21) ( Figure 4D) . 347
To assess whether the augmented β-cell mass was maintained during adult life, we analyzed the 348 pancreas from mice at four months of age (P120). BPA 100 mice showed a decrease in pancreatic β-349 cell mass that was statistically significant when comparing to control by Student's t-test but not 350 significant using ANOVA ( Figure 4E ). Moreover, these animals presented a higher fasted glucose and 351 a tendency to be glucose intolerant ( Figure 4F) . Genes upregulated at P30 were equally expressed 352 than Controls at P120 (Supplemental Material Figure 1) . 353
354
BPA treatment increases β-cell proliferation and decreases β-cell apoptosis at P30 355
To study the contribution of β-cell proliferation in the observed increase in pancreatic β-cell mass, we 356 measured incorporation of BrdU as an indicator of cell proliferation. The percentage of BrdU positive 357 nuclei augmented in BPA10 and BPA100 ( Figure 5A and B), indicating that under this conditions cell 358 proliferation was increased. Apoptosis is another important factor in determining β-cell mass. In 359 BPA10 and BPA100 apoptosis measured by TUNEL staining decreased when compared to Control 360 ( Figure 5C ). These experiments indicate that the elevated β-cell mass in BPA treated animals maybe a 361 consequence of increased β-cell division and decreased apoptosis. 362
363
E2 treatment partially imitates BPA action on β-cell mass at P30 364
BPA can exert its effects through different modes of action, although it is mainly considered a 365 xenoestrogen (57). Therefore, we thought in a possible mimetic action of the natural hormone, 17-β 366 estradiol (E2). To evaluate this possibility, we treated pregnant dams with 10µg/kg/day E2 and 367 pancreas were analyzed to analyze β-cell mass, β-cell division and apoptosis. When animals were 368 treated with a higher concentration of E2 (100 µg/kg/day), the offspring died during gestation. 369
At P30, the offspring of E2-treated mice presented increased β-cell mass compared to control ( Figure  370 6 A,B), yet nuclei labeled with BrdU ( Figure 6C ) was not different. In addition, the gene profile 371 observed in E2 treated animals indicated that only some of the genes, increased by BPA (Cdc20 and 372 Figure 2) . Apoptosis, however, was highly 373 reduced by E2 exposure ( Figure 6D ). These experiments suggest that BPA partially imitates E2 action 374 under these experimental conditions. 375
Ube2c) was elevated by E2 (Supplemental Material
DISCUSSION 376
Exposure to EDCs is now considered a risk factor for type-2 diabetes, obesity and other metabolic 377 disorders (1, 58, 59) . Bisphenol-A is one of the most studied EDCs, including its link with T2D and 378 obesity in animal models and humans (41, 60, 61). Here we have treated pregnant mice from days 9 to 379 16 of gestation with BPA at doses of, 10 and 100 µg/kg/day. We focused our study on male offspring 380 at P0, P21, P30 and P120. We only studied males because in a previous study from our group, using 381 the same treatment, we did not find any change in female phenotype (36). As explained in the 382 Introduction, we considered that the dose of 10 µg/kg/day was low because it is below the current 383 lowest observed effect level (LOAEL) (50µg/kg/day) established by the U.S.-EPA, and similar to the 384 temporary tolerable daily intake by the European Food and Safety Authority (4µg/kg/day). In any 385 case, it must be noted that this study was designed to test a mechanistically-driven hypothesis not to 386 specifically address human risk. At P30, microarray analysis showed that a large amount of genes 387 related to cell division were upregulated in pancreatic islets from offspring mice indicating that 388 pancreatic β-cell mass could be affected by BPA exposure during pregnancy. Accordingly, pancreatic 389 β-cell mass was increased in the offspring of pregnant females exposed to BPA, even in response to 390 the lowest exposure dose of 10 µg/kg/day. This augmented β-cell mass was likely because a rise in 391 cell division, as manifested by BrdU incorporation, together with a decrease in apoptosis. 392
Analysis of blood parameters showed hyperinsulinemia but equal glucose levels together with 393 hyperleptinemia in the non-fasting state (eating ad libitum). Hyperinsulinemia means excessive 394 insulin secretion, which is manifested in this study by an increase in plasma C-peptide in BPA treated 395 animals. Because GSIS measured ex vivo was either decreased (BPA10) or unchanged (BPA100), it is 396 plausible that the hyperinsulinemia detected in the non-fasting state was due to the incremented β-cell 397 mass. This hyperinsulinemic state may be a reaction to counteract insulin resistance or a direct action 398 of BPA on pancreas growth. Unaffected glucose tolerance and insulin sensitivity indicate that the 399 increase in β-cell mass was unlikely a consequence of any of these two factors. Remarkably, the fact 400 that β-cell mass was already increased at birth it is inconsistent with an adaptive response to decreased 401 insulin sensitivity. In rodents, the fastest expansion of β-cell mass occurs during late fetal gestation, 402 increasing at a rate of 100% per day (62). An 80% or more is attributed to neogenesis while a 20% or 403 less to cell division (63). Pancreas development in mice stars about embryonic days E9 and E10, with 404 the formation of pancreatic buds. Endocrine cells appear between days E10 and E13.5, but it is mostly 405 at 13.5 when all hormone secreting cells are apparent and at E15 cells are differentiated into exocrine 406 and endocrine cells. By E18 pancreatic islet cells are already visible (64, 65) . Based in the 407 experiments showed here we propose that BPA exposure between E9 and E16, altered β-cell mass 408 during fetal development. During the neonatal period there is still growth of β-cell mass but at a lower 409 rate than during late fetal growth. Neogenesis is still occurring during the first week of age yet, after 410 that period, the β-cell mass expands by replication (66). The results showed here, demonstrate that β-411 cell replication is increased at weaning and P30 and consequently, it suggests that β-cell mass is 412
augmented by β-cell division. This may occur as a consequence of the overexpression of genes related 413 to cell division as demonstrated in the microarray's data. 414
About the time of weaning a "wave" of apoptosis occurs, decreasing the growth of β-cell mass (67, 415 68). The fact that apoptosis is highly decreased in BPA10 and BPA100 animals compared to Control 416 indicates that BPA exposure increased β-cell mass not only by incrementing cell division, but by 417 diminishing apoptosis as well. 418
During life, it is essential to regulate β-cell mass growth in response to different physiological 419 circumstances, including increased body mass and pregnancy (69-72). In addition, metabolic stress 420 during pregnancy such as intrauterine growth restriction disrupts pancreatic β-cell mass growth as 421 well as β-cell function, producing serious consequences in offspring later in life (73, 74) . It is 422 plausible that the changes in β-cell mass from birth to the first month of life described in this work 423 affect the phenotype later in life. Studies using mice treated with BPA during the same window of 424 time as here, show a phenotype of altered glucose and lipid homeostasis later in life (from 3 to 6 425 months old). The phenotype includes: glucose intolerance, altered insulin sensitivity, 426 hyperinsulinemia, increase in body weight, adiposity, alterations in adipokines, NEFA and 427 triglyceride levels in blood as well as triglyceride accumulation in the liver (36, 39, 40) . Here, the 428 augmented growth of β-cell mass observed during the first month of age it is not maintained. 429
Moreover, at P120 mice presented a great tendency to a decreased β-cell mass together with altered 430 glucose tolerance, particularly in BPA100. In the present work, increased β-cell mass at P30 is 431 associated with hyperinsulinemia in at libitum fed animals, which is the regular situation in mice. As a 432 consequence, they will have a constant hyperinsulinemia compared with vehicle treated animals. 433
Could this excess of insulin signaling disrupt glucose homeostasis later in life? It is widely accepted 434 that hyperinsulinemia is simply a compensatory mechanism to counteract insulin resistance. However, 435 hyperinsulinemia may precede insulin resistance in T2D (75-78) and it has been demonstrated that it 436 may contribute to obesity and insulin resistance in ob/ob mice (79). Hyperinsulinemia drives to 437 obesity in genetically designed mice, in which it is possible to control the amount of insulin available 438 (80). In adult mice, it was proposed that EDCs, including BPA, induce insulin resistance and 439 hyperinsulinemia in the non-fasting state (81, 82) . It has been demonstrated ex vivo and in vitro that 440 pollutants, including EDCs, directly stimulate insulin secretion and/or insulin content generating an 441 increase in β cell function in response to nutrients (28, 78, 83) . This hyperinsulinemia may be, at least 442 in part, responsible of the insulin resistance caused by some EDCs such as 83) . 443
It is always difficult to demonstrate whether hyperinsulinemia is a consequence of insulin resistance 444 or the opposite. We propose that alterations in β-cell mass at birth and early life provokes an 445 hyperinsulimemia in the non-fasting state that may influence the phenotype later in life favoring 446 insulin resistance, hyperinsulinemia, hyperleptinemia, increase in body weight and other factors 447 related to metabolic syndrome (36, 37, 39, 40) . 448 449 BPA passes the placental barrier (84) and therefore it may act directly in the fetus. It is known that 450
BPA acts as a potent xenoestrogen in β-cells via binding to extranuclearly located estrogen receptor 451
ERα and ERβ (29, 30 ), yet it is a weak estrogen when acting via the classical ERs pathways working 452 as transcription factors (26). In addition, BPA may act trough other mechanisms of action (57). Here 453 we show that the natural hormone E2 partially mimicked BPA actions at 1 month of age. Both, 454 BPA10 and E10 increased β-cell mass at P30 and decreased apoptosis, however, BrdU incorporation 455 only augmented in BPA treated mice and gene related to cell cycle were activated to a less extent in 456 E10 than BPA10 mice. Therefore, it is possible that BPA acts as a potent xenoestrogen for some of 457 the effects seeing here such as β-cell mass regulation but we cannot discard the involvement of 458 mechanisms other than a direct action in fetal cell mediated by estrogen receptors. In addition to the 459 effect that BPA exposure in utero exerts in offspring, BPA exposure during days 9 to 16 of pregnancy 460 alters blood glucose homeostasis in the mothers at the end of pregnancy. These alterations include: 461 glucose intolerance, insulin resistance, hyperinsulinemia and hyperleptinemia, higher levels of 462 triglycerides and glycerol compared to Controls (36). Therefore, the final phenotype of offspring may 463 not only be influenced by a direct action of BPA on fetal development but also by the abnormal 464 glucose homeostasis of the mothers, as it occurs in the LIRKO mouse model of insulin resistance 465 (14). In the later model, nonetheless, the effect of maternal hyperinsulinemia and transient 466 hyperglycemia decreases β-cell proliferation and islet number. 467
In the present study, we evaluated the early effects of maternal exposure to BPA on glucose 468 homeostasis, pancreatic β-cell mass and function. We found that offspring mice presented an 469 augmented β-cell mass associated with hyperinsulinemia in the absence of insulin resistance and 470 insulin oversecretion. The change in β-cell mass was associated with an increase in the expression of 471 genes related to cell division and cell cycle regulation. In addition, BPA treated animals presented 472 elevated β-cell division and decreased apoptosis. This early changes may affect the phenotype later in 473 life and may be responsible of the alterations in glucose homeostasis already described. 474
Further research is needed to fully understand the mechanisms underlying the increase in β-cell mass 475 and β-cell proliferation at birth and during the first weeks of life, and whether this predisposes to type 476 2 diabetes with aging in animal models and humans. Holm-Sidak post hoc test, P (maternal treatment), P (Control vs. BPA10) < 0.001; P (Control vs. BPA 507 100) < 0.001; P (BPA10 vs. BPA100) < 0.01; body weight data on P5: ANOVA followed by Holm-508
Sidak post hoc test, P (maternal treatment), P (Control vs. BPA10) < 0.01; P (BPA10 vs. BPA100) < 509 0.05); body weight data on P12: Kruskal-Wallis ANOVA on ranks followed by Dunn´s post hoc test, 510 P (maternal treatment), P (Control vs. BPA100) < 0.05, P (BPA10 vs. BPA100) < 0.05); body weight 511 data on P16: (Kruskal-Wallis ANOVA on ranks followed by Dunn´s post hoc test, P (maternal 512 treatment), P (Control vs. BPA100) < 0.05, P (BPA10 vs. BPA100) < 0.05) (n = 42-77 animals from 513 10-12 litters). B) Weight comparison at P30. BPA100 was significantly different compared to Control 514 and BPA10. ANOVA followed by Holm-Sidak post hoc test, P (maternal treatment), P (Control vs. 515 BPA100) < 0.05, P (BPA10 vs. BPA100) < 0.05) (n=32-43 animals from 7-10 litters). C) 516
Intraperitoneal glucose tolerance test were performed on the three groups at P30 (n=6-14 animals 517 from 6-10 litters). D) Intraperitoneal insulin tolerance test were performed on the three groups at P30 518 (n=15-17 animals 15-17 litters). E) Insulin secretion from islets exposed to 3, 8 and 16 mM glucose 519 for 1 hour, in animals from the three different groups at P30. Kruskal-Wallis ANOVA on Ranks 520 followed by Dunn´s post hoc test, P (maternal treatment) P (Control vs. BPA10) <0.05 (n=10-15 521 groups of five islets per condition from 6-8 animals from 6-7 litters) F) Insulin content from isolated 522 islets at P30 ANOVA followed by Holm-Sidak´s post hoc test, P (maternal treatment), P (Control vs. 523 BPA10) <0.05 (n=31-35 groups of five islets per condition from 6-8 animals from 6-7 litters). 524
Data are expressed as mean ± SEM.; *Control vs. BPA10 or BPA 100; *, P < 0.05, **, P < 0.01, ***, 525 P < 0.001; # BPA10 vs. BPA100, #, P < 0.05, ##, P < 0.01. BPA10 or BPA 100; *, P < 0.05; $, P < 0.05, Student´s t-test compared to Control. N=4-6 from 15 537 mice/group from 6-9 litters. Details on statistics used: Ccnb1 (Kruskal-Wallis ANOVA on Ranks 538 followed by Dunn´s post hoc test, P (maternal treatment), P (Control vs. BPA100) <0.05). Cdk1 539 (ANOVA followed by Dunnett´s post hoc test, P (maternal treatment), P (Control vs. BPA100) < 540 0.05). Mt1 (Kruskal-Wallis ANOVA on Ranks followed by Dunn´s post hoc test, P (maternal 541 treatment), P (Control vs. BPA100) <0.05). Procr (ANOVA followed by Dunnet´s post hoc test, P 542 (maternal treatment), P (Control vs. BPA10) <0.05; P (Control vs. BPA 100) < 0.05). Idi1 (ANOVA 543 followed by Dunnet´s post hoc test, P (maternal treatment), P (Control vs. BPA10) <0.05; (n=4-6 544 samples from 15 mice/group from 6-7 litters)). Pdx-1, ANOVA followed by Dunnet´s post hoc test, P 545 (maternal treatment), P (Control vs. BPA10) <0.05; (n=4-6 samples from 15 mice/group from 6-9 546 litters). Mt2, Spa17 and Birc5 were not statistically significant by ANOVA, yet these genes were 547 significantly down-regulated in BPA10 samples compared to Control by Student's t-test (P (maternal 548 treatment), P (Control vs. BPA10) <0.05; (n=4-6 samples from 15 mice/group from 6-7 litters)). 549 550 FIGURE 4. A) Relative β-cell mass calculated as the percentage of the insulin-positive area over the 551 total pancreas area. Pancreas were obtained from P30 animals. ANOVA followed by Holm-Sidak´s 552 post hoc test, P (maternal treatment), P (Control vs. BPA10) <0.05; (n=5 mice/group from 5 litters). 553 B) Analysis of pancreatic β-cell mass (milligrams per pancreas), calculated as the ratio of the insulin-554 positive area over the total pancreas area, multiplied by pancreas weight at the same age as in A. 555 ANOVA followed by Holm-Sidak´s post hoc test, P (maternal treatment), P (Control vs. BPA10) 556 <0.05, P (Control vs. BPA100) <0.05; (n=5 mice/group from 5 litters). C) Relative β-cell mass 557 calculated as the percentage of the insulin-positive area over the total pancreas area. Pancreas were 558 obtained from P0 animals. Kruskal-Wallis ANOVA on Ranks followed by Dunn´s post hoc test, P 559 (maternal treatment) P (Control vs. BPA10) <0.05; P (Control vs. BPA100) <0.05; (n=8 mice/group 560 from 7-8 litters). D) β-cell mass calculated as the ratio of the insulin-positive area over the total 561 pancreas area multiplied by pancreas weight. Pancreas were obtained from P21 animals. ANOVA 562 followed by Dunnett´s post hoc test, P (maternal treatment) P (Control vs. BPA10) <0.01; P (Control 563 vs. BPA100) <0.001; (n=8 mice/group from 7-8 litters). E) β-cell mass calculated as the ratio of the 564 insulin-positive area over the total pancreas area multiplied by pancreas weight. Pancreas were 565 obtained from P120 animals. Significant using Student's t-test (P (maternal treatment), P (Control vs. 566 BPA100) <0.05. No statistically significant by ANOVA (n= 5 mice/group from 5 litters). F) 567
Intraperitoneal glucose tolerance test performed in the three groups. Open circles for Control, filled 568 circles for BPA10, filled squares for BPA100 (n= 5 mice/group from 5 litters). Data are expressed as 569 the mean ± SEM. *Control vs. BPA10 or BPA 100, # BPA10 vs. BPA100; *, P <0.05, **, P <0.01, 570 ***, P < 0.001. $, P <0.05, Student´s t-test compared to Control. or E210µg/kg/day (E10). B) Analysis of pancreatic β-cell mass (milligrams per pancreas), calculated 586 as the ratio of the insulin-positive area over the total pancreas area, multiplied by pancreas weight in 587 the same conditions as in A (n=8 mice/group from 8 litters). C) Percentage of BrdU-positive β-cells in 588 control and E2 mice at P30 (n = 6 mice/group from 6 litters). B) Analysis of apoptotic β-cells 589 quantified in pancreas sections using a fluorescein in situ cell death detection assay (TUNEL) in 590 control and E10 (n=7-8 mice/group from 7 litters). Data are expressed as the mean ± SEM, and 591 statistical significance was determined using Student´s t-test compared to Control. *Control vs. 592 BPA10 or BPA 100; *, P < 0.05. 593 594 Table 2 . Serum hormone and metabolite levels in animals exposed to BPA in utero. n= insulin 595 fasted state 9-14 animals from 8-14 litters; insulin non-fasting state 41-51 animals from 39-51 litters; 596 c-peptide 20-24 animals from 20-24 litters; leptin 18-24 animals from 18-23 litters; cholesterol 12-22 597 animals from 8-22 litters; triglyceride 9-11 animals from 8-9 litters and NEFA 15 animals from 8-9 598 litters. Data are expressed as mean±SEM. Significance was determined using ANOVA one way 599 followed by Holm-Sidak post hoc test. When data did not pass the parametric test, we used Kruskal-600 Wallis ANOVA on ranks followed by Dunn's test. See below for further details. *Control vs. BPA10 601 or BPA 100; *, P < 0.05; # BPA10 vs. BPA100, #, P < 0.05. Insulin non-fasting, Kruskal-Wallis 602 ANOVA on ranks followed by Dunn´s method, P (maternal treatment), P (Control vs. BPA10) < 603 0.05, P (Control vs. BPA100) < 0.05; (n=41-51 animals from 39-51 litters). C-Peptide, ANOVA 604 followed by Holm-Sidak post hoc test, P(maternal treatment), P (Control vs. BPA10) < 0.05, P 605 (Control vs. BPA100) < 0.05; (n=20-24 animals from 20-24 litters. Leptin, Kruskal-Wallis ANOVA 606 on ranks followed by Dunn´s post hoc test, P (maternal treatment), P (Control vs. BPA10) < 0.05, P 607 (Control vs. BPA100) < 0.05, P (BPA10 vs. BPA100) < 0.05; (n=18-24 animals from 18-23 litters). 608 e, 609 610 611
